Literature DB >> 12944598

Coronary arteries: contrast-enhanced MR imaging with SH L 643A--experience in 12 volunteers.

Christoph U Herborn1, Jörg Barkhausen, Ingo Paetsch, Peter Hunold, Marianne Mahler, Kohkan Shamsi, Eike Nagel.   

Abstract

PURPOSE: To assess SH L 643A for three-dimensional breath-hold and respiratory-gated magnetic resonance (MR) imaging in the depiction of coronary arteries.
MATERIALS AND METHODS: Twelve healthy male volunteers underwent either three-dimensional breath-hold (n = 6) or respiratory-gated (n = 6) coronary MR angiography before and after intravenous injection of 0.1 mmol SH L 643A per kilogram of body weight. For nonenhanced and contrast material-enhanced examinations, signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) measurements were obtained. Image quality was assessed in consensus with a five-point scale. Statistical analysis of nonenhanced and contrast-enhanced images was based on a two-tailed paired Student t test. A P value at the.05 significance level was used.
RESULTS: Overall statistically significant improvement in CNR was observed after administration of SH L 643A compared with that on nonenhanced images (8.7 +/- 5.3 [SD] vs 23.6 +/- 7.2, P <.01). While SNR of contrast-enhanced images showed improvement over that of nonenhanced images, the difference was not statistically significant (25.4 +/- 0.8 vs 30.2 +/- 16.8, P >.2). Image quality improved from a mean of 3.1 +/- 0.8 for nonenhanced images to 4.0 +/- 0.8 (P <.01) for contrast-enhanced images.
CONCLUSION: SH L 643A causes significant improvement of the blood-myocardium contrast enhancement at coronary MR angiography compared with that with nonenhanced sequences. Copyright RSNA, 2003

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12944598     DOI: 10.1148/radiol.2291021033

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  9 in total

Review 1.  MRI in coronary artery disease.

Authors:  Jörg Barkhausen; Peter Hunold; Kai-Uwe Waltering
Journal:  Eur Radiol       Date:  2004-09-04       Impact factor: 5.315

Review 2.  Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations.

Authors:  Wassana Wijagkanalan; Shigeru Kawakami; Mitsuru Hashida
Journal:  Pharm Res       Date:  2010-12-23       Impact factor: 4.200

3.  Magnetic resonance coronary angiography with Vasovist: in-vivo T1 estimation to improve image quality of navigator and breath-hold techniques.

Authors:  Kai Nassenstein; Kai-Uwe Waltering; Sebastian Kelle; Thomas Schlosser; Frank Breuckmann; Stefan Maderwald; Peter Hunold; Eike Nagel; Jörg Barkhausen
Journal:  Eur Radiol       Date:  2007-08-14       Impact factor: 5.315

4.  Contrast-enhanced whole-heart coronary MRI with bolus infusion of gadobenate dimeglumine at 1.5 T.

Authors:  Peng Hu; Jonathan Chan; Long H Ngo; Jouke Smink; Beth Goddu; Kraig V Kissinger; Lois Goepfert; Thomas H Hauser; Neil M Rofsky; Warren J Manning; Reza Nezafat
Journal:  Magn Reson Med       Date:  2010-11-30       Impact factor: 4.668

5.  Design of nanovectors for therapy and imaging of cardiovascular diseases.

Authors:  Omolola Eniola-Adefeso; Michael J Heslinga; Tyrone M Porter
Journal:  Methodist Debakey Cardiovasc J       Date:  2012-01

Review 6.  Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.

Authors:  Jessica Wahsner; Eric M Gale; Aurora Rodríguez-Rodríguez; Peter Caravan
Journal:  Chem Rev       Date:  2018-10-16       Impact factor: 60.622

7.  Coronary computed tomography and magnetic resonance imaging.

Authors:  Birgit Kantor; Eike Nagel; Paul Schoenhagen; Jörg Barkhausen; Thomas C Gerber
Journal:  Curr Probl Cardiol       Date:  2009-04       Impact factor: 5.200

Review 8.  MR angiography with blood pool contrast agents.

Authors:  Jens Bremerich; Deniz Bilecen; Peter Reimer
Journal:  Eur Radiol       Date:  2007-07-17       Impact factor: 5.315

9.  Patient acceptance of noninvasive and invasive coronary angiography.

Authors:  Eva Schönenberger; Dirk Schnapauff; Florian Teige; Michael Laule; Bernd Hamm; Marc Dewey
Journal:  PLoS One       Date:  2007-02-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.